Why Today Is the Best Time to Buy Johnson & Johnson [JNJ] Stock at $151.55

Johnson & Johnson [JNJ] shares are up more than 7.86% this year and recently increased 0.02% or $2.58 to settle at $151.55. Analysts expect JNJ to grow earnings at a 4.38% annual rate over the next 5 years. JNJ has a short ratio of 2.13. This implies that the market is currently less bullish on the outlook for JNJ.

On 3, December 2020, Johnson & Johnson Names Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General to its Board of Directors. According to news published on Yahoo Finance, Johnson & Johnson (NYSE: JNJ) announced today that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General has been appointed to its Board of Directors.

Analyst Birdseye View:

The most recent analyst activity for Johnson & Johnson [NYSE:JNJ] stock was on April 22, 2020, when it was Upgrade with a Buy rating from BofA/Merrill, which also raised its 12-month price target on the stock from $150 to $175. Before that, on April 28, 2020, UBS Recapitulated a Neutral rating and elevated its amount target to $160. On March 05, 2020, Citigroup Initiated a Buy rating and boosted its price target on this stock to $163. On December 19, 2019, Barclays Upgrade an Overweight rating and increased its price target to $173. On December 17, 2019, Morgan Stanley Upgrade an Overweight rating and increased its price target to $170. On November 20, 2019, Cantor Fitzgerald Initiated an Overweight rating and boosted its amount on this stock to $160. On October 16, 2019, Atlantic Equities Upgrade a Neutral rating. On October 11, 2019 Bernstein Upgrade an Outperform rating and elevated its amount target to $155.

In the past 52 weeks of trading, this stock has oscillated between a low of $109.16 and a peak of $157.00. Right now, according to Wall Street analyst the average 12-month amount target is $166.55. At the most recent market close, shares of Johnson & Johnson [NYSE:JNJ] were valued at $151.55. According to the average price forecast, investors can expect a potential return of 2.25%.


Johnson & Johnson [NYSE:JNJ] most recently reported quarterly sales of 21.08 billion, which represented growth of 1.70%. This publicly-traded organization’s revenue is $621,127 per employee, while its income is $114,365 per employee. This company’s Gross Margin is currently 65.80%, its Operating Margin is 23.60%, its Pretax Margin is +21.10, and its Net Margin is +18.41. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 9.73, 25.36, 24.16 and 17.37 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 32.54 and the whole liability to whole assets at 18.18. It shows enduring liability to the whole principal at 30.87 and enduring liability to assets at 0.17 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 150.02 points at 1st support level, the second support level is making up to 148.49. But as of 1st resistance point, this stock is sitting at 152.61 and at 153.67 for 2nd resistance point.

Johnson & Johnson [JNJ] reported its earnings at $2.2 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $1.98/share signifying the difference of 0.22 and 11.10% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were $1.67 calling estimates for $1.49/share with the difference of 0.18 depicting the surprise of 12.10%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Johnson & Johnson [NYSE:JNJ] is 1.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.54. Now if looking for a valuation of this stock’s amount to sales ratio it’s 4.76, it’s amount to book ratio is 6.45 and showing 24.25 of P/E (TTM) ratio.

Insider Stories

The most recent insider trade was by Wengel Kathryn E, EVP, Chief GSC Officer, and it was the sale of 16115.0 shares on Sep 02. McEvoy Ashley, the EVP, WW Chair, Medical Devices, completed a sale of 29000.0 shares on Jul 28. On Jun 30, JOHNSON & JOHNSON, 10% Owner, completed a purchase of 0.72 million shares.